STOCK TITAN

Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Merck (NYSE: MRK) has announced its upcoming fourth-quarter and full-year 2024 sales and earnings conference call, scheduled for February 4, 2025, at 9:00 a.m. ET. The call will feature company executives presenting Merck's Q4 performance and providing guidance for 2025.

The event will be accessible to institutional investors, analysts, journalists, and the general public through a live audio webcast. Participants can also join via phone using the toll-free numbers: (800) 369-3351 (U.S. and Canada) or (517) 308-9448, with access code 9818590. A replay of the webcast, along with financial disclosures and presentation slides, will be available on Merck's website.

Merck (NYSE: MRK) ha annunciato la sua prossima conferenza telefonica sui risultati delle vendite e degli utili del quarto trimestre e dell'intero anno 2024, programmata per 4 febbraio 2025, alle 9:00 ET. Durante la chiamata, i dirigenti dell'azienda presenteranno le performance del Q4 di Merck e forniranno indicazioni per il 2025.

L'evento sarà accessibile a investitori istituzionali, analisti, giornalisti e al pubblico generale tramite una trasmissione audio in diretta. I partecipanti possono anche unirsi via telefono utilizzando i numeri verdi: (800) 369-3351 (USA e Canada) o (517) 308-9448, con il codice di accesso 9818590. Una registrazione della webcast, insieme alle dichiarazioni finanziarie e alle diapositive della presentazione, sarà disponibile sul sito web di Merck.

Merck (NYSE: MRK) ha anunciado su próxima conferencia telefónica sobre las ventas y ganancias del cuarto trimestre y del año completo 2024, programada para 4 de febrero de 2025, a las 9:00 a.m. ET. Durante la llamada, los ejecutivos de la empresa presentarán el desempeño del Q4 de Merck y ofrecerán orientación para 2025.

El evento será accesible para inversores institucionales, analistas, periodistas y el público en general a través de una transmisión de audio en vivo. Los participantes también pueden unirse por teléfono usando los números gratuitos: (800) 369-3351 (EE. UU. y Canadá) o (517) 308-9448, con el código de acceso 9818590. Una repetición de la transmisión, junto con las declaraciones financieras y las diapositivas de presentación, estará disponible en el sitio web de Merck.

머크(Merck) (NYSE: MRK)는 2024년 4분기 및 연간 판매 및 수익에 대한 컨퍼런스 콜을 2025년 2월 4일 오전 9:00 ET에 진행할 예정이라고 발표했습니다. 이 통화에서는 회사 경영진이 머크의 4분기 실적을 발표하고 2025년 전망을 제공할 것입니다.

이 행사는 기관 투자자, 애널리스트, 언론인 및 일반 대중이 실시간 오디오 웹캐스트를 통해 접근할 수 있습니다. 참여자는 또한 무료 전화번호(800) 369-3351(미국 및 캐나다) 또는 (517) 308-9448로 전화하여 액세스 코드 9818590을 사용하여 참여할 수 있습니다. 웹캐스트의 재방송과 재무 공개 사항, 프레젠테이션 슬라이드는 머크의 웹사이트에서 확인할 수 있습니다.

Merck (NYSE: MRK) a annoncé sa prochaine conférence téléphonique sur les ventes et les bénéfices du quatrième trimestre et de l'année entière 2024, prévue pour le 4 février 2025, à 9h00 ET. Lors de cet appel, les responsables de l'entreprise présenteront les performances de Merck au quatrième trimestre et fourniront des orientations pour 2025.

L'événement sera accessible aux investisseurs institutionnels, analystes, journalistes et au grand public via un webinaire audio en direct. Les participants peuvent également rejoindre par téléphone en utilisant les numéros sans frais : (800) 369-3351 (États-Unis et Canada) ou (517) 308-9448, avec le code d'accès 9818590. Un enregistrement du webinaire, ainsi que les déclarations financières et les diapositives de présentation, sera disponible sur le site Web de Merck.

Merck (NYSE: MRK) hat seine bevorstehende Telefonkonferenz zu den Verkaufs- und Ertragszahlen des vierten Quartals und des gesamten Jahres 2024 für 4. Februar 2025, um 9:00 Uhr ET angekündigt. In diesem Anruf werden die Unternehmensvorstände die Leistungen von Merck im Q4 präsentieren und einen Ausblick für 2025 geben.

Die Veranstaltung wird für institutionelle Investoren, Analysten, Journalisten und die breite Öffentlichkeit über ein Live-Audio-Webcast zugänglich sein. Teilnehmer können auch per Telefon mit den gebührenfreien Nummern: (800) 369-3351 (USA und Kanada) oder (517) 308-9448 in die Konferenz einsteigen, unter Verwendung des Zugangscodes 9818590. Eine Wiederholung des Webcasts, zusammen mit finanziellen Offenlegungen und Präsentationsfolien, wird auf der Website von Merck verfügbar sein.

Positive
  • None.
Negative
  • None.

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2024 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, Feb. 4. During the call, company executives will provide an overview of Merck’s performance for the fourth quarter and outlook for 2025.

Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com.

All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free) or (517) 308-9448 and using the access code 9818590.

About Merck

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Media Contacts:

Robert Josephson

(203) 914-2372

robert.josephson@merck.com

Michael Levey

(215) 872-1462

michael.levey@merck.com

Investor Contacts:

Peter Dannenbaum

(732) 594-1579

peter.dannenbaum@merck.com

Steven Graziano

(732) 594-1583

steven.graziano@merck.com

Source: Merck & Co., Inc.

FAQ

When is Merck (MRK) reporting Q4 and full-year 2024 earnings?

Merck will report its Q4 and full-year 2024 earnings on Tuesday, February 4, 2025, at 9:00 a.m. ET.

How can investors access Merck's (MRK) Q4 2024 earnings call?

Investors can access the call through a live audio webcast or by phone using (800) 369-3351 (U.S./Canada) or (517) 308-9448 with access code 9818590.

What will be discussed in Merck's (MRK) Q4 2024 earnings call?

The call will cover Merck's fourth-quarter performance, full-year 2024 results, and outlook for 2025.

Where can I find Merck's (MRK) Q4 2024 earnings materials after the call?

The earnings materials, including the webcast replay, news release, supplemental financial disclosures, and presentation slides will be available at www.merck.com.

Merck & Co., Inc.

NYSE:MRK

MRK Rankings

MRK Latest News

MRK Stock Data

251.88B
2.53B
0.06%
79.42%
1.27%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
KENILWORTH